Get the Stockscreener App
1.26
5.88%
0.07
After Hours:
1.24
-0.02
-1.59%
Pds Biotechnology Corporation stock is traded at $1.26, with a volume of 782.56K.
It is up +5.88% in the last 24 hours and down -16.00% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.19
Open:
$1.22
24h Volume:
782.56K
Relative Volume:
1.27
Market Cap:
$56.18M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.0769
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-5.97%
1M Performance:
-16.00%
6M Performance:
-58.00%
1Y Performance:
-73.47%
1-Day Range:
$1.19
$1.305
1-Week Range:
$1.16
$1.49
52-Week Range:
$1.16
$5.00
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.26 | 56.18M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com India
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo Finance
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail
Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock - Investing.com India
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock - Investing.com India
PDS Biotechnology Directors Increase Holdings with Recent Purchases - TradingView
PDSB stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
PDSB stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com India
EMV Capital portfolio company PDS Biotechnology raises $11mln - Proactive Investors Australia
PDS Biotechnology Launches Registered Direct Offering; Shares Up -February 27, 2025 at 12:02 pm EST - Marketscreener.com
PDS Biotechnology Corp. to Host Earnings Call - ACCESS Newswire
PDS Biotech secures $11 million in direct offering By Investing.com - Investing.com South Africa
PDS Biotech secures $11 million in direct offering - Investing.com India
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology - The Manila Times
Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World
PDS Biotech stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Nigeria
Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News
PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times
PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times
Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan
PDSB stock touches 52-week low at $1.3 amid market challenges - MSN
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in - One News Page
PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):